Law360, New York (October 14, 2009) -- Pfizer Inc. has laid down the sword with two Mylan Inc. subsidiaries over the pharmaceutical giant's anti-fungal medication Vfend, agreeing to an out-of-court settlement and license agreement that will allow a generic version of the drug to hit the U.S. market starting in the first quarter of 2011.
Pfizer's deal with Mylan Pharmaceuticals Inc. and Matrix Laboratories Ltd. is limited to the tablet form of Vfend — known generically as voriconazole — and doesn't cover Pfizer’s Vfend products...
